Bacterial distribution and antimicrobial drug resistance were monitored in patients with bacterial bloodstream infections in rural hospitals in Ghana. In 2001–2002 and in 2009,
In Africa, fever is usually a synonym for malaria. However, evidence exists that a large proportion of fever of unknown origin (FUO) can be attributed to bacterial bloodstream infections (BBSI). Although
In 2000 in hospitals in Ghana, we began to establish bacteriologic laboratories, which since then have participated in a biannual quality control program. For this quality control, 3 encoded bacterial species and their resistance to various antimicrobial drugs must be correctly identified. Three of these hospitals took part in comparative epidemiologic studies of FUO during October 2001–April 2002 and again during August–September 2009 with the objective of establishing a rational treatment approach (
Location of populations in a study of bacteremia and antimicrobial drug resistance over time, Ghana.
This study was approved by the ethical committee of the University Medical Center, Göttingen, Germany, and the participating hospitals in Ghana. The study design, patient selection, and diagnostic approaches were identical in both study periods; FUO was defined as fever >38.5°C of >1 week’s duration without a clear clinical or organ-specific diagnosis. During the first study period, 409 patients with a wide range of ages (interquartile range 26 years) were investigated. The second study period included 258 patients with a similar age distribution (interquartile range 27 years).
Blood film microscopy was used for malaria diagnosis. Bacteremia was determined by blood cultures; 2 mL or 5 mL of blood was incubated in 20 mL or 50 mL of locally made brain–heart infusion broth for
Of the 212 bacterial isolates recovered from the blood cultures in the first study period, 145 (68.4%) indicated a putative agent of septicemia (
| Variable | July 2001–April 2002 | July–September 2009 | |||
| Total | Positive for | Total | Positive for | ||
| No. patients with fever of unknown origin | 409 | NA | 258 | NA | |
| No. | 85/354 (24.0) | NA | 75/177 (42.4) | NA | |
| Total no. bacterial isolates | 212 | 51 (24.1) | 99 | 14 (14.1) | |
| Skin flora contaminants | 67 | 24 (35.8) | 51 | 10 (19.6) | |
| Potential pathogens | 145 (100.0) | 27 (18.6) | 48 (100.0) | 4 (8.3) | |
| 100 (69.0) | 20 (20.0) | 24 (50.0) | 4 (16.7) | ||
| Typhi | 59 (40.7) | 11 (18.6) | 15 (31.3) | 2 (13.3) | |
| Paratyphi | 1 (0.7) | NF | 0 | NF | |
| Nontyphoid‡ | 40 (27.6) | 9 (22.5) | 9 (18.8) | 2 (22.2) | |
| 16 (11.0) | 3 (18.8) | 3 (6.3) | NF | ||
| 10 (6.9) | 1 (10.0) | 8 (16.7) | NF | ||
| 7 (4.8) | 2 (28.6) | 5 (10.4) | NF | ||
| Other§ | 12 (8.3) | 1 (8.3) | 8 (16.7) | NF | |
*Values are no. (%) except as indicated. The total number of potential pathogens for each study period was set as 100%. Coagulase-negative staphylococci, microcooci, and bacilli were judged as skin flora contaminants. The ratio of
| Bacteria type and years | PEN | OXA | AMP | CEF | GEN | SMX | CMP | CIP |
| 2001–2002 | 93.3 | 1.7 | 0 | 86.7 | 88.3 | 0 | ||
| 2009 | 100 | 0 | 0 | 100 | 100 | 0 | ||
| Nontyphoid | ||||||||
| 2001–2002 | 100 | 20.0 | 12.5 | 90.0 | 82.5 | 0 | ||
| 2009 | 100 | 0 | 0 | 88.9 | 77.8 | 0 | ||
| 2001–2002 | 100 | 50.0 | 60.0 | 80.0 | 80.0 | 0 | ||
| 2009 | 100 | 87.5 | 37.5 | 62.5 | 50.0 | 50.0 | ||
| Nonfermenters | ||||||||
| 2001–2002 | 91.7 | 75.0 | 16.7 | 41.7 | 100 | 0 | ||
| 2009 | 100 | 100 | 15.4 | 53.8 | 92.3 | 0 | ||
| 2001–2002 | 81.3 | 0 | 81.3 | 0 | 0 | 68.8 | ||
| 2009 | 100 | 0 | 100 | 0 | 0 | |||
| All bacteria | ||||||||
| 2001–2002 | 93.6 | 18.9 | 10.7 | 72.1 | 84.3 | 0 | ||
| 2009 | 100 | 41.7 | 10.4 | 72.9 | 84.4 | 8.9 |
*Blank cells indicate no testing performed. PEN, penicillin; OXA, oxacillin; AMP, ampicillin; CEF, cefuroxime; GEN, gentamicin; SMX, trimethoprim/sulfamethoxazole; CMP, chloramphenicol; CIP, ciprofloxacin.
To analyze the influence of ciprofloxacin on pathogen distribution and antimicrobial drug resistance in BBSI, in 2009 we initiated a follow-up study. During the second study period, pathogenic bacteria were identified in 48 (48.5%) of 99 blood cultures; the rate of
Although an extraordinarily high percentage of chloramphenicol resistance was obvious, this drug still was considered the first choice treatment for typhoid fever in 2001 in Ghana. Therefore, the high rate of
In 2001–2002, most bacteria were susceptible to ciprofloxacin (
Although ciprofloxacin proved to be effective against
When we assessed the situation in individual regions, notable differences were obvious. Comprising 47.5% of all BBSI, typhoid fever was most prevalent in Assin Foso in 2001–2002. In contrast, not even 1 case occurred in 2009. Analyzing the situation in that urban area, the following conditions were found: 1) sanitation was improved; 2) additional toilets were established; 3) ciprofloxacin was widely used in hospital for treating infections; and 4) ciprofloxacin was easily available at local street traders. Although the broad application of ciprofloxacin has to be critically discussed, the observed absence of typhoid fever in Assin Foso is impressive.
In contrast,
Although Ghana implemented several measures to control typhoid, our study found that, depending on the region,
We thank the patients in Ghana for participating in this study and Nicholas Amgborme, Marcelina Gruszka, Paul Harriban, Kwame Buadu Mahdi, and Samuel Numafo for their help in collecting the bacterial isolates from blood cultures.
This study was partly supported by a grant from Bayer Social Health Care Programs.
This article is dedicated to our friend, Nicholas Amgborme from Eikwe, who passed away much too soon.
Dr Uwe Groß is head of the Institute of Medical Microbiology at the University Medical Center Göttingen, Germany, and since 2000 has helped establish bacteriology laboratories in missionary hospitals in rural settings in Ghana. His current research concentrates on campylobacteriosis, toxoplasmosis, and infectious diseases caused by pathogenic fungi.